Angela Mastronuzzi: Our aim was to evaluate the feasibility of VEN plus Cy-Topo in children with relapsed/refractory neuroblastoma

Angela Mastronuzzi, Head of Neuro-Oncology Unit at the Bambino Gesù Children’s Hospital, shared on LinkedIn:

“Happy to share my team’s recently published paper with Nature Portfolio!

‘Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series’

The prognosis of relapsed/refractory (R/R) neuroblastoma (NB) is dismal, calling for new therapeutic strategies. Venetoclax (VEN) is a highly selective, potent, orally bioavailable, BCL-2 inhibitor small-molecule that showed a synergistic effect with cyclophosphamide and topotecan (Cy-Topo) in murine NB models. Our aim was to evaluate the feasibility of VEN plus Cy-Topo in children with relapsed/refractory neuroblastoma.

Special thanks for the support by the Italian Ministry of Health with Current Research funds.”

For the article click here.
Source: Angela Mastronuzzi/LinkedIn